NeuroOne Medical Technologies Corporation (NMTC)
NASDAQ: NMTC · Real-Time Price · USD
0.5860
+0.0506 (9.45%)
At close: Apr 23, 2025, 4:00 PM
0.5584
-0.0276 (-4.71%)
Pre-market: Apr 24, 2025, 4:11 AM EDT
NMTC Revenue
NeuroOne Medical Technologies had revenue of $3.27M in the quarter ending December 31, 2024, with 234.90% growth. This brings the company's revenue in the last twelve months to $5.75M, up 104.21% year-over-year. In the fiscal year ending September 30, 2024, NeuroOne Medical Technologies had annual revenue of $3.45M with 1.33% growth.
Revenue (ttm)
$5.75M
Revenue Growth
+104.21%
P/S Ratio
2.90
Revenue / Employee
$338,207
Employees
17
Market Cap
27.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.45M | 45.37K | 1.33% |
Sep 30, 2023 | 3.41M | 1.29M | 60.73% |
Sep 30, 2022 | 2.12M | 1.88M | 772.60% |
Sep 30, 2021 | 242.96K | -1.68M | -87.39% |
Sep 30, 2020 | 1.93M | - | - |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
NMTC News
- 20 hours ago - NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain - GlobeNewsWire
- 7 days ago - NeuroOne® Issues Letter to Shareholders - GlobeNewsWire
- 9 days ago - NeuroOne® OneRF® Technology Success Story Featured on Fox News - GlobeNewsWire
- 19 days ago - Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet - Benzinga
- 19 days ago - NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update - GlobeNewsWire
- 5 weeks ago - NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - GlobeNewsWire